The estimated Net Worth of Filip Dubovsky is at least $1.65 Million dollars as of 17 June 2024. Filip Dubovsky owns over 13,904 units of Novavax stock worth over $989,554 and over the last few years he sold NVAX stock worth over $657,637. In addition, he makes $0 as Senior Vice President and Chief Medical Officer at Novavax.
Filip has made over 8 trades of the Novavax stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 13,904 units of NVAX stock worth $85,927 on 17 June 2024.
The largest trade he's ever made was selling 47,312 units of Novavax stock on 14 May 2024 worth over $657,637. On average, Filip trades about 11,896 units every 41 days since 2023. As of 17 June 2024 he still owns at least 80,517 units of Novavax stock.
You can see the complete history of Filip Dubovsky stock trades at the bottom of the page.
Dr. Filip Dubovsky M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Dubovsky brings more than 20 years of infectious disease experience to Novavax. He joins Novavax from AstraZeneca, where he was Head of Clinical Engagement and Policy and Deputy Chief Medical Officer for clinical affairs. He joined MedImmune, the global biologics arm of AstraZeneca, where he oversaw the clinical development of early and late-stage infectious disease and vaccine assets. Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH's Malaria Vaccine Initiative. He has co-authored more than 50 peer-reviewed scientific publications and currently sits on the Board of Directors of the Sabin Institute. Dr. Dubovsky earned his Master of Public Health degree from Johns Hopkins University and his Doctor of Medicine degree from the University of Alabama. He completed his pediatric training at Stanford University, his pediatric infectious disease fellowship at the Center for Vaccine Development at the University of Maryland, and his preventive medicine training at Johns Hopkins University.
Filip's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, MD, 20878.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: